+

WO2007009702A2 - Composes de pyrazoline substitues, leur preparation et leur utilisation comme medicaments - Google Patents

Composes de pyrazoline substitues, leur preparation et leur utilisation comme medicaments Download PDF

Info

Publication number
WO2007009702A2
WO2007009702A2 PCT/EP2006/006976 EP2006006976W WO2007009702A2 WO 2007009702 A2 WO2007009702 A2 WO 2007009702A2 EP 2006006976 W EP2006006976 W EP 2006006976W WO 2007009702 A2 WO2007009702 A2 WO 2007009702A2
Authority
WO
WIPO (PCT)
Prior art keywords
optionally
group
branched
substituted
disorders
Prior art date
Application number
PCT/EP2006/006976
Other languages
English (en)
Other versions
WO2007009702A3 (fr
Inventor
Maria Rosa Cuberes Altisen
Original Assignee
Laboratorios Del Dr. Esteve, S.A.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from EP05384022A external-priority patent/EP1743889A1/fr
Application filed by Laboratorios Del Dr. Esteve, S.A. filed Critical Laboratorios Del Dr. Esteve, S.A.
Publication of WO2007009702A2 publication Critical patent/WO2007009702A2/fr
Publication of WO2007009702A3 publication Critical patent/WO2007009702A3/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/06—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Definitions

  • the present invention relates to substituted pyrazoline compounds, methods for their preparation, medicaments comprising these compounds as well as their use for the preparation of a medicament for the treatment of humans and animals.
  • Triglycerides are the chemical form in which most fat exists in food as well as in the body. Triglycerides are present in blood plasma and, in association with cholesterol, form the plasma lipids. Triglycerides in blood plasma are derived from fats consumed directly or are synthesized from e.g. carbohydrates. Superfluous food intake is converted to triglycerides and transported to fat cells to be stored. Elevated triglycerides may also be a consequence of disease states, such as untreated diabetes mellitus. Excess of triglycerides in plasma (hypertriglyceridemia) is linked to the occurrence of coronary artery disease and possibly other disorders.
  • the present invention relates to a substituted pyrazoline compound of general formula
  • R 1 represents hydrogen or a linear or branched, substituted or unsubstituted, saturated or unsaturated Ci- 4 -alkyl group
  • R 7 represents hydrogen, a linear or branched Ci- ⁇ -alkyI group, a linear or branched d-e-alkoxy group, a halogen atom, CH 2 F 1 CHF 2 , CF 3 , CN, OH, NO 2 ,
  • R 10 and optionally R 11 for each substituent independently represent linear or branched Ci ⁇ alkyl;
  • Another aspect of the present invention relates to a substituted pyrazoline compound of general formula
  • R 1 represents hydrogen or a linear or branched, substituted or unsubstituted, saturated or unsaturated C- M -alkyl group
  • Preferred linear or branched, saturated or unsaturated aliphatic groups which may be substituted by one or more substituents, may preferably be selected from the group consisting of methyl, ethyl, n-propyl, isopropyl, n-butyl, iso-butyl, sec-butyl, tert- butyl, n-pentyl, n-hexyl, n-heptyl, n-octyl, n-nonyl, n-decyl, vinyl, ethinyl, propenyl, propinyl, butenyl and butinyl.
  • alkyl and cycloalkyl radicals are understood as meaning saturated and unsaturated (but not aromatic), branched, unbranched and cyclic hydrocarbons, which can be unsubstituted or mono- or polysubstituted.
  • Ci -2 -alkyl represents C1- or C2-alkyl
  • Ci- 3 -alkyl represents C1-, C2- or C3-alkyl
  • d- 4 -alkyl represents C1-, C2-, C3- or C4-alkyl
  • Ci -5 -alkyl represents C1-, C2-, C3-, C4-, or C5-alkyl
  • C 1-6 -alkyl represents C1-, C2-, C3-, C4-, C5- or C6-alkyl
  • Ci- r alkyl represents C1-, C2-, C3-, C4-, C5-, C6- or C7-alkyl
  • Ci- ⁇ -alkyI represents C1-, C2-, C3-, C4-, C5-, C6-, C7- or C8-alkyl
  • Ci.io-alkyl represents C1-, C2-, C3-, C4-, C5-, C6
  • C3-4-cycloalkyl represents C3- or C4-cycloalkyl
  • C 3-5 - cycloalkyl represents C3-, C4- or C5-cycloalkyl
  • C 3 -6-cycloalkyl represents C3-, C4-, C5- or C6-cycloalkyl
  • C 3 -7-cycloalkyl represents C3-, C4-, C5-, C6- or C7-cycloalkyl
  • C 3 - 8 -cycloalkyl represents C3-, C4-, C5-, C6-, C7- or C8-cycloalkyl
  • C4- 5 -cycloalkyl represents C4- or C5-cycloalkyl
  • C- ⁇ -cycloalkyl represents C4-, C5- or C6-cycloalkyl
  • C.j- 7 -cycloalkyl represents C4-, C5-, C6- or C7-cycloalkyl
  • cycioalkyl also includes saturated cycloalkyls in which one or 2 carbon atoms are replaced by a heteroatom, S, N or O.
  • mono- or polyunsaturated, preferably monounsaturated, cycloalkyls without a heteroatom in the ring also in particular fall under the term cycioalkyl as long as the cycioalkyl is not an aromatic system.
  • alky I and cycioalkyl radicals are preferably methyl, ethyl, vinyl (ethenyl), propyl, allyl (2-propenyl), 1-propinyl, methylethyl, butyl, 1- methylpropyl, 2-methyl propyl, 1 ,1-dimethylethyl, pentyl, 1,1-dimethylpropyl, 1 ,2- dimethylpropyl, 2,2-dimethylpropyl, hexyl, 1-methylpentyl, cyclopropyl, 2- methylcyclopropyl, cyclopropylmethyl, cyclobutyl, cyclopentyl, cyclopentyl methyl, cyclohexyl, cycloheptyl, cyclooctyl, and also adamantyl, (if substituted also CHF 2 , CF 3 or CH 2 OH) as well as pyrazolinone, oxopyr
  • Particularly preferred substituents here are F, Cl and OH.
  • the hydrogen radical can also be replaced by OCi -3 -alkyl or Ci- 3 -alkyl (in each case mono- or polysubstituted or unsubstituted), in particular methyl, ethyl, n-propyl, i-propyl, CF 3 , methoxy or ethoxy.
  • (CH 2 ) 3 - ⁇ is to be understood as meaning -CH 2 -CH 2 -CH 2 -, -CHrCH 2 -CHr CHr, -CHrCHrCHrCHr and -CHrCH 2 -CHrCHrCHr, (CH 2 )i-4 is to be understood as meaning -CHr, -CHrCHr, -CHrCHrCHr and -CHrCHrCHr, (CH 2 )4-5 is to be understood as meaning -CHrCHrCHr and -CHrCHrCHr CHrCHr, etc.
  • aryl radical is understood as meaning ring systems with at least one aromatic ring but without heteroatoms even in only one of the rings. Examples are phenyl, naphthyl, fluoranthenyl, fluorenyl, tetralinyl or indanyl, in particular 9H-fluorenyl or anthracenyl radicals, which can be unsubstituted or monosubstituted or polysubstituted.
  • a heteroaryl radical is understood as meaning heterocyclic ring systems which have at least one unsaturated ring and can contain one or more heteroatoms from the group consisting of nitrogen, oxygen and/or sulfur and can also be mono- or polysubstituted.
  • heteroaryls are furan, benzofuran, thiophene, benzothiophene, pyrrole, pyridine, pyrimidine, pyrazine, quinoline, isoquinoline, phthalazine, benzo-1 ,2,5-thiadiazole, benzothiazole, indole, benzotriazole, benzodioxolane, benzodioxane, carbazole and quinazoline.
  • substituted is understood as meaning substitution of the aryl or heteroaryl by R, OR, a halogen, preferably F and/or Cl, a CF 3 , a CN, an NO 2 , an NRR, a Ci-e-alkyl (saturated), a Ci- ⁇ -alkoxy, a C 3-8 - cycloalkoxy, a C 3 - S -CyClOaI kyl or a C 2 - 6 -alkylene.
  • salt is to be understood as meaning any form of the active compound used according to the invention in which it assumes an ionic form or is charged and is coupled with a counter-ion (a cation or anion) or is in solution.
  • a counter-ion a cation or anion
  • complexes of the active compound with other molecules and ions in particular complexes which are complexed via ionic interactions. Especially this covers any "physiologically acceptable salt”.
  • physiologically acceptable salt to be understood as being equivalent and interchangeable with “physiologically acceptable salt” means in the context of this invention any salt that is physiologically tolerated (most of the time meaning not being toxi ⁇ ? especially not caused by the counter-ion) if used appropriately for a treatment especially if used on or applied to humans and/or mammals.
  • physiologically acceptable salts can be formed with cations or bases and in the context of this invention is understood as meaning salts of at least one of the compounds used according to the invention - usually a (deprotonated) acid - as an anion with at least one, preferably inorganic, cation which is physiologically tolerated - especially if used on humans and/or mammals.
  • the salts of the alkali metals and alkaline earth metals are particularly preferred, and also those with NH4, but in particular (mono)- or (di)sodium, (mono)- or (di)potassium, magnesium or calcium salts.
  • physiologically acceptable salts can also be formed with anions or acids in the context of this invention is understood as meaning salts of at least one of the compounds used according to the invention - usually protonated, for example on the nitrogen - as the cation with at least one anion which are physiologically tolerated - especially if used on humans and/or mammals.
  • the salt formed with a physiologically tolerated acid that is to say salts of the particular active compound with inorganic or organic acids which are physiologically tolerated - especially if used on humans and/or mammals.
  • physiologically tolerated salts of particular acids are salts of: hydrochloric acid, hydrobromic acid, sulfuric acid, methanesulfonic acid, formic acid, acetic acid, oxalic acid, succinic acid, malic acid, tartaric acid, mandelic acid, fumaric acid, lactic acid or citric acid.
  • solvate is to be understood as meaning any form of the active compound according to the invention in which this compound has attached to it via non-covalent binding another molecule (most likely a polar solvent) especially including hydrates (mono- and multihydrates) and alcoholates, e.g. methanolate and ethanolate.
  • a polar solvent especially including hydrates (mono- and multihydrates) and alcoholates, e.g. methanolate and ethanolate.
  • the compounds of the invention are also meant to include compounds which differ only in the presence of one or more isotopically enriched atoms.
  • compounds having the present structures except for the replacement of a hydrogen by a deuterium or tritium, or the replacement of a carbon by 13 C- or 14 C-enriched carbon or 15 N-enriched nitrogen are within the scope of this invention.
  • at least one of R 2 , R 3 or R 4 represents hydrogen, while at least one of R 2 , R 3 or R 4 is different from hydrogen.
  • R 7 represents hydrogen
  • R 2 , R 3 and R 4 independently of each other represent hydrogen, a linear or branched C-i- ⁇ - alkyl group, a halogen atom, or CF3, preferably R 2 , R 3 and R 4 independently of each other represent hydrogen, methyl, ethyl, F, Cl, Br and CF 3 .
  • R 5 and R 6 independently of each other represent a linear or branched group, a halogen atom, or CF 3 , preferably R 5 and R 6 independently of each other represent methyl, ethyl, F, Cl, Br and CF 3 .
  • R 2 represents a chlorine atom in the 4-position of the phenyl ring, while R 3 and R 4 represent hydrogen.
  • R 1 represents hydrogen, methyl or ethyl, preferably hydrogen.
  • the compound of general formula I is represented by a compound of general formula Il
  • R 1 represents hydrogen or a linear or branched, substituted or unsubstituted, saturated or unsaturated, C 1-4 -alkyl group
  • R 12 or R 13 independently of each other represent a linear or branched C1- 6 - alkyl group, a linear or branched Ci- 6 -alkoxy group, a halogen atom, CH 2 F, CHF 2 , CF 3 , CN 1 OH, NO 2 , SH, NH 2 , hydrogen, methyl, ethyl, F, Cl, Br and CF 3 ,
  • R 14 or R 15 independently of each other represent a linear or branched C 1-6 - alkyl group, a linear or branched Ci- ⁇ -alkoxy group, a halogen atom, CH 2 F, CHF 2 , CF 3 , CN, OH, NO 2 , SH, NH 2 , methyl, ethyl, F, Cl, Br and CF 3 ,
  • R 12 and R 13 independently of each other represent hydrogen, a linear or branched Ci. 6 -alkyl group, a halogen atom, or CF 3 , preferably R 12 and R 13 independently of each other represent hydrogen, methyl, ethyl, F, Cl, Br and CF 3 .
  • R 14 , and R 15 independently of each other represent a linear or branched d- ⁇ -alkyl group, a halogen atom, or CF 3 , preferably R 14 and R 15 independently of each other represent methyl, ethyl, F, Cl, Br and CF 3 .
  • R 13 represents Cl and R 12 represents hydrogen.
  • R 14 and R 15 each represent Cl.
  • R 1 represents hydrogen, methyl or ethyl, preferably hydrogen.
  • Another preferred embodiment of the invention covers also any prodrug of the compounds of the invention described above as well as any medicament comprising this and any use thereof; especially including their esters and ethers.
  • Examples of well known methods of producing a prodrug of a given acting compound are known to those skilled in the art and can be found e.g. in Krogsgaard-Larsen et al., Textbook of Drugdesign and Discovery, Taylor & Francis (April 2002).
  • it also covers mixtures of the compounds of the invention (according to formulas I and II) described above with their corresponding opposite enantiomer according to formula XX
  • Another aspect of the invention is a combination of compounds comprising at least one substituted pyrazoline compound of general formula I
  • R 1 represents hydrogen or a linear or branched, substituted or unsubstituted, saturated or unsaturated, Ci-4-alkyl group,
  • R 16 represents an optionally at least mono-substituted phenyl group
  • R 17 represents an optionally at least mono-substituted phenyl group
  • R 18 represents a saturated or unsaturated, optionally at least mono- substituted, optionally at least one heteroatom as ring member containing cycloaliphatic group, which may be condensed with an optionally at least mono-substituted mono- or polycyclic ring system, or an optionally at least mono-substituted aryl or heteroaryl group, which may be condensed with an optionally at least mono-substituted mono- or polycyclic ring system, or an - NR 19 R 20 -moiety,
  • R 19 and R 20 represent a hydrogen atom, an unbranched or branched, saturated or unsaturated, optionally at least mono-substituted aliphatic radical, a saturated or unsaturated, optionally at least mono- substituted, optionally at least one heteroatom as ring member containing cycloaliphatic group, which may be condensed with an optionally at least mono-substituted mono- or polycyclic ring system, or an optionally at least mono-substituted aryl or heteroaryl group, which may be condensed with an optionally at least mono-substituted mono- or polycyclic ring system and/or bonded via a linear or branched alkylene group, an -S ⁇ 2-R 21 -moiety, or an - NR 22 R 23 -moiety, with the proviso that R 19 and R 20 do not identically represent hydrogen,
  • R 21 represents a linear or branched, saturated or unsaturated, optionally at least mono-substituted aliphatic group, a saturated or unsaturated, optionally at least mono-substituted, optionally at least one heteroatom as ring member containing cycloaliphatic group, which may be condensed with a mono- or polycyclic ring-system, or an optionally at least mono-substituted aryl or heteroaryl group, which may be condensed with a mono- or polycyclic ring system and/or bonded via a linear or branched alkylene group,
  • R 22 and R 23 identical or different, represent a hydrogen atom, an unbranched or branched, saturated or unsaturated, optionally at least mono-substituted aliphatic radical, a saturated or unsaturated, optionally at least mono- substituted, optionally at least one heteroatom as ring member containing cycloaliphatic group, which may be condensed with an optionally at least mono-substituted mono- or polycyclic ring system, or an optionally at least mono-substituted aryl or heteroaryl group, which may be condensed with an optionally at least mono-substituted mono- or polycyclic ring system and/or bonded via a linear or branched alkylene group,
  • stereoisomers optionally in form of one of the stereoisomers, preferably enantiomers or diastereomers, a racemate or in form of a mixture of at least two of the stereoisomers, preferably enantiomers and/or diastereomers, in any mixing ratio, or a corresponding N-oxide thereof, or a corresponding salt thereof, or a corresponding solvate thereof.
  • At least one of R 2 , R 3 or R 4 represents hydrogen, while at least one of R 2 , R 3 or R 4 is different from hydrogen.
  • at least on of R 5 , R 6 or R 7 represents hydrogen, while at least one R 5 , R 6 or R 7 is different from hydrogen.
  • R 2 , R 3 and R 4 independently of each other represent hydrogen, a linear or branched group, a halogen atom, or CF3, preferably R 2 , R 3 and R 4 independently of each other represent hydrogen, methyl, ethyl, F, Cl, Br and CF 3 .
  • R 5 , R 6 and R 7 independently of each other represent hydrogen, a linear or branched group, a halogen atom, or CF 3 , preferably R 5 , R 6 and R 7 independently of each other represent hydrogen, methyl, ethyl, F 1 Cl, Br and CF 3 .
  • R 2 represents a chlorine atom in the 4-position of the phenyl ring, while R 3 and R 4 represent hydrogen.
  • R 5 and R 6 each represent a chlorine atom in the 2- and 4-position of the phenyl ring, while R 7 represents hydrogen.
  • R 1 represents hydrogen, methyl or ethyl, preferably hydrogen.
  • R 1 represents hydrogen or a linear or branched, substituted or unsubstituted, saturated or unsaturated, Ci-4-alkyl group,
  • R 12 , R 13 , R 14 or R 15 independently of each other represent a linear or branched Ci- 6 -alkyl group, a linear or branched group, a halogen atom, CH 2 F 1 CHF 2 , CF 3 , CN 1 OH, NO 2 , SH, NH 2 , hydrogen, methyl, ethyl, F, Cl, Br and CF 3 ,
  • R 12 and R 13 independently of each other represent hydrogen, a linear or branched Ci_ 6 -alkyl group, a halogen atom, or CF 3 , preferably R 12 and R 13 independently of each other represent hydrogen, methyl, ethyl, F, Cl, Br and CF 3 .
  • R 14 , and R 15 independently of each other represent hydrogen, a linear or branched Ci- 6 -alkyl group, a halogen atom, or CF 3 , preferably R 14 and R 15 independently of each other represent hydrogen, methyl, ethyl, F, Cl, Br and CF 3 .
  • R 13 represents Cl and R 12 represents hydrogen.
  • R 14 and R 15 each represent Cl.
  • R 1 represents hydrogen, methyl or ethyl, preferably hydrogen.
  • R 18 represents a saturated or unsaturated, optionally at least mono-substituted, optionally at least one heteroatom as ring member containing C 3 . 8 cycloaliphatic group, which may be condensed with an optionally at least mono-substituted mono- or polycyclic ring system, or an optionally at least mono-substituted, 5- or 6-membered aryl or heteroaryl group, which may be condensed with an optionally at least mono-substituted mono- or polycyclic ring system, or an -NR 19 R 2 °-moiety, preferably R 18 represents a saturated, optionally at least mono-substituted, optionally one or more nitrogen-atoms as ring member containing C 3 - 8 cycloaliphatic group, which may be condensed with an optionally at least mono-substituted mono- or polycyclic ring system, or an
  • R 19 and R 20 identical or different, represent a hydrogen atom, an unbranched or branched, saturated or unsaturated, optionally at least mono-substituted radical, a saturated or unsaturated, optionally at least mono-substituted, optionally at least one heteroatom as ring member containing C 3 - 8 -cycloaliphatic group, which may be condensed with an optionally at least mono-substituted mono- or polycyclic ring system, or an optionally at least mono-substituted, 5- or 6-membered aryl or heteroaryl group, which may be condensed with an optionally at least mono-substituted mono- or polycyclic ring system and/or bonded via a methylene (-CH2-) or ethylene (-CH2-CH 2 )-group, an - SC>2-R 21 -moiety, or an -NR ⁇ R ⁇ -
  • R 21 represents a linear or branched, saturated or unsaturated, optionally at least mono-substituted Ci -6 aliphatic group, a saturated or unsaturated, optionally at least mono-substituted, optionally at least one heteroatom as ring member containing C 3 -8 cycloaliphatic group, which may be condensed with a mono- or polycyclic ring-system, or an optionally at least mono- substituted, 5- or 6-membered aryl or heteroaryl group, which may be condensed with a mono- or polycyclic ring system and/or bonded via a methylene (-CH 2 -) or ethylene (-CH 2 -CH 2 )-group, preferably R 21 represents a C 1-6 -alkyl group, a saturated, optionally at least mono-substituted cycloaliphatic group, which may be condensed with a mono- or
  • R 22 and R 23 represent a hydrogen atom, an unbranched or branched, saturated or unsaturated, optionally at least mono-substituted Ci -6 aliphatic radical, a saturated or unsaturated, optionally at least mono-substituted, optionally at least one heteroatom as ring member containing C ⁇ a cycloaliphatic group, which may be condensed with an optionally at least mono-substituted mono- or polycyclic ring system, or an optionally at least mono-substituted, 5- or 6 membered aryl or heteroaryl group, which may be condensed with an optionally at least mono-substituted mono- or polycyclic ring system and/or bonded via a methylene (-CH 2 -) or ethylene (-CH2-CH 2 )-group, preferably R 22 and R 23 , identical or different, represent a hydrogen atom, an unbranched or branched, saturated or unsaturated, optionally at least mono-substitute
  • R 16 represents a phenyl ring, which is mono-substituted with a halogen atom, preferably a chlorine atom, in its 4-position,
  • R 17 represents a phenyl ring, which is di-substituted with two halogen atoms, preferably chlorine atoms, in its 2- and 4-position,
  • R 18 represents a pyrrolidinyl group, a piperidinyl group, a piperazinyl group, a homo-piperazinyl group, a morpholinyl group, or an -NR 19 R 2 °-moiety,
  • R 19 represents a hydrogen atom or a linear or branched C-i- ⁇ -alkyl group
  • R 20 represents a linear or branched Ci -6 alkyl group, an -SO 2 -R 21 -moiety, a pyrrolidinyl group, a piperidinyl group, a piperazinyl group, a homo-piperazinyl group, a morpholinyl group, a triazolyl group, whereby each of the heterocyclic rings may be substituted with one or more, identical or different, Ci- ⁇ -alkyI groups, and
  • R 21 represents a phenyl group, which is optionally substituted with one or more
  • Ci- 6 alkyl groups which may be identical or different
  • stereoisomers optionally in form of one of the stereoisomers, preferably enantiomers or diastereomers, a racemate or in form of a mixture of at least two of the stereoisomers, preferably enantiomers and/or diastereomers, in any mixing ratio, or a corresponding N-oxide thereof, or a corresponding salt thereof, or a corresponding solvate thereof.
  • the present invention also provides a process for the preparation of substituted pyrazoline compounds of general formula I or II, wherein R 1 is hydrogen, given above, in that at least one benzaldehyde compound of general formula III
  • G represents an OR group with R being a branched or unbranched Ci- 6 alkyl radical or G represents an O ' K group with K being a cation, preferably an anorganic kation, more preferably an alkali metal kation, most preferably sodium, to yield a compound of general formula (V)
  • R 2 , R 3 , R 4 , R 5 , R 6 and R 7 have the meaning as given above, which is optionally isolated and/or optionally purified, and optionally esterified to an alkyl-ester if in the substituted pyrazoline compound of general formula I or Il according to the invention
  • R 1 is a linear or branched, substituted or unsubstituted, saturated or unsaturated, d-4-alkyl group.
  • the reaction of the benzaldehyde compound of general formula III with a pyruvate compound of general formula IV is preferably carried out in the presence of at least one base, more preferably in the presence of an alkali metal hydroxide such as sodium hydroxide or potassium hydroxide or an alkali metal methoxide such as sodium methoxide, as described, for example, in Synthetic communications, 26(11), 2229-33, (1996).
  • an alkali metal hydroxide such as sodium hydroxide or potassium hydroxide
  • an alkali metal methoxide such as sodium methoxide
  • Reaction temperature as well as the duration of the reaction may vary over a broad range.
  • Preferred reaction temperatures range from -10 0 C to the boiling point of the reaction medium.
  • Suitable reaction times may vary for example from several minutes to several hours.
  • reaction of the benzaldehyde compound of general formula III with a pyruvate compound of general formula IV is carried out under acid catalysed conditions, more preferably by refluxing the mixture in dichloromethane in the presence of copper(ll)trifluoromethanesulfonate as described, for example, in Synlett, (1 ), 147-149, 2001.
  • acid catalysed conditions more preferably by refluxing the mixture in dichloromethane in the presence of copper(ll)trifluoromethanesulfonate as described, for example, in Synlett, (1 ), 147-149, 2001.
  • the respective description is hereby incorporated by reference and forms part of the disclosure.
  • reaction of the compound of general formula (V) with an optionally substituted phenyl hydrazin of general formula (Vl) is preferably carried out in a suitable reaction medium such as or ethers such as dioxane or tetrahydrofurane or mixtures of at least two of these afore mentioned compounds.
  • a suitable reaction medium such as or ethers such as dioxane or tetrahydrofurane or mixtures of at least two of these afore mentioned compounds.
  • said reaction may be carried out in the presence of an acid, whereby the acid may be organic such as acetic acid and/or inorganic such as hydrochloric acid.
  • the reaction may also be carried out in the presence of a base such as piperidine, piperazine, sodium hydroxide, potassium hydroxide, sodium methoxide or sodium ethoxide, or a mixture of at least two of these bases may also be used.
  • Reaction temperature as well as the duration of the reaction may vary over a broad range
  • the carboxylic group of the compound of general formula (VII) may be activated for further reactions by the introduction of a suitable leaving group according to conventional methods well known to those skilled in the art.
  • the compounds of general formula (VII) are transferred into an acid chloride, an acid anhydride, a mixed anhydride, a Ci -4 alkyl ester, an activated ester such as p- nitrophenylester.
  • Other well known methods for the activation of acids include the activation with N.N-dicyclohexylcarbodiimide or benzotriazol-N- oxotris(dimethylamino) phosphonium hexafluorophosphate (BOP)).
  • said activated compound of general formula (VII) is an acid chloride
  • it is preferably prepared by reaction of the corresponding acid of general formula (VII) with thionyl chloride or oxalyl chloride, whereby said chlorinating agent is also used as the solvent.
  • an additional solvent may be used.
  • Suitable solvents include hydrocarbons such as benzene, toluene or xylene, halogenated hydrocarbons such as dichloromethane, chloroform or carbon tetrachloride, ethers such as diethyl ether, dioxane, tetrahydrofurane or dimethoxyethane. Mixtures of two or more solvents from one class or two or more solvents from different classes may also be used.
  • Preferred reaction temperature range from 0° C to the boiling point of the solvent and reaction times from several minutes to several hours.
  • said activated compound of general formula (VII) is a mixed anhydride
  • said anhydride may preferably be prepared, for example, by reaction of the corresponding acid of general formula (VII) with ethyl chloroformiate in the presence of a base such as triethylamine or pyridine, in a suitable solvent.
  • substituted pyrazoline compounds of general formula I or Il themselves are obtained in form of a mixture of stereoisomers, particularly enantiomers or diastereomers, said mixtures may be separated by standard procedures known to those skilled in the art, e.g. chromatographic methods or fractionalized crystallization with chiral reagents. It is also possible to obtain pure stereoisomers via stereoselective synthesis.
  • the present invention also provides a process for the preparation of salts of substituted pyrazoline compounds of general formula I or Il and stereoisomers thereof, wherein at least one compound of general formula I or Il having at least one basic group is reacted with at least one inorganic and/or organic acid, preferably in the presence of a suitable reaction medium.
  • suitable reaction media include, for example, any of the ones given above.
  • Suitable inorganic acids include hydrochloric acid, hydrobromic acid, phosphoric acid, sulfuric acid, nitric acid
  • suitable organic acids are e.g. citric acid, maleic acid, fumaric acid, tartaric acid, or derivatives thereof, p-toluenesulfonic acid, methanesulfonic acid or camphersulfonic acid.
  • the present invention also provides a process for the preparation of salts of substituted pyrazoline compounds of general formula I or Il or stereoisomers thereof, wherein at least one compound of general formula I or Il having at least one acidic group is reacted with one or more suitable bases, preferably in the presence of a suitable reaction medium.
  • suitable bases are e.g. hydroxides, carbonates or alkoxides, which include suitable cations, derived e.g. from alkaline metals, alkaline earth metals or organic cations, e.g. [NH n R-Mi] + , wherein n is 0, 1, 2, 3 or 4 and R represents a branched or unbranched Ci-4-alkyl-radical.
  • suitable reaction media are, for example, any of the ones given above.
  • Solvates, preferably hydrates, of the substituted pyrazoline compounds of general formula I or II, of corresponding stereoisomers, of corresponding N-oxides or of corresponding salts thereof may also be obtained by standard procedures known to those skilled in the art.
  • Substituted pyrazoline compounds of general formula I or II, which comprise nitrogen-atom containing saturated, unsaturated or aromatic rings may also be obtained in the form of their N-oxides by methods well known to those skilled in the art.
  • substituted pyrazoline compounds of general formula I and Il given below, their stereoisomers, corresponding N-oxides, corresponding salts thereof and corresponding solvates are toxicologically acceptable and are therefore suitable as pharmaceutical active substances for the preparation of medicaments.
  • substituted pyrazoline compounds of general formula (I) and (II) given below, stereoisomers thereof, N-oxides thereof, corresponding salts and corresponding solvates have the property to regulate triglyceride levels in blood plasma.
  • substituted pyrazoline compounds of general formula X given below stereoisomers thereof, N-oxides thereof, corresponding salts and corresponding solvates have a high affinity to cannabinoid receptors, particularly cannabinoid 1 (CBi)-receptors, i.e. they act as antagonists on these receptors.
  • cannabinoid 1 (CBi)-receptors i.e. they act as antagonists on these receptors.
  • these pyrazoline compounds show litte or no development of tolerance during treatment particularly with respect to food intake. After ending the treatment with the pyrazoline compounds, reduced increase of body weight is found compared to the pre-treatment level.
  • Another aspect of the present invention relates to a Medicament comprising at least one substituted pyrazoline compound of general formula I or Il according to the invention and optionally one or more pharmaceutically acceptable excipients.
  • Another aspect of the present invention relates to a Medicament comprising at least one substituted pyrazoline compound of general formula I
  • R 1 represents hydrogen or a linear or branched, substituted or unsubstituted, saturated or unsaturated, Ci-4-alkyl group,
  • Another aspect of the present invention relates to a Medicament comprising at least one substituted pyrazoline compound of general formula I
  • R 1 represents hydrogen or a linear or branched, substituted or unsubstituted, saturated or unsaturated, Chalky! group
  • neither of R 2 , R 3 or R 4 may represent SO 2 R 8 in para-position with R 8 being methyl.
  • At least one of R 2 , R 3 or R 4 represents hydrogen, while at least one of R 2 , R 3 or R 4 is different from hydrogen.
  • At least one of R 5 , R 6 or R 7 represents hydrogen, while at least one R 5 , R 6 or R 7 is different from hydrogen.
  • R 2 , R 3 and R 4 independently of each other represent hydrogen, a linear or branched group, a halogen atom, or CF 3 , preferably R 2 , R 3 and R 4 independently of each other represent hydrogen, methyl, ethyl, F, Cl, Br and CF 3 .
  • R 5 , R 6 and R 7 independently of each other represent hydrogen, a linear or branched Ci-6-alkyl group, a halogen atom, or CF 3 , preferably R 5 , R 6 and R 7 independently of each other represent hydrogen, methyl, ethyl, F, Cl, Br and CF 3 .
  • R 2 represents a chlorine atom in the 4-position of the phenyl ring, while R 3 and R 4 represent hydrogen.
  • R 5 and R 6 each represent a chlorine atoms in the 2- and A- position of the phenyl ring, while R 7 represents hydrogen.
  • R 1 represents hydrogen, methyl or ethyl, preferably hydrogen.
  • the compound according to formula I is represented by a compound of general formula (II)
  • R represents hydrogen or a linear or branched, substituted or unsubstituted, saturated or unsaturated, Ci- 4 -alkyl group
  • R 12 , R 13 , R 14 or R 15 independently of each other represent a linear or branched C- ⁇ -6-alkyl group, a linear or branched C-i-e-alkoxy group, a halogen atom,
  • R 12 and R 13 independently of each other represent hydrogen, a linear or branched Ci- 6 -alkyl group, a halogen atom, or CF 3 , preferably R 12 and R 13 independently of each other represent hydrogen, methyl, ethyl, F, Cl, Br and CF 3 .
  • R 14 , and R 15 independently of each other represent hydrogen, a linear or branched Ci- 6 -alkyl group, a halogen atom, or CF 3 , preferably R 14 and R 15 independently of each other represent hydrogen, methyl, ethyl, F, Cl, Br and CF 3 .
  • R 13 represents Cl and R 12 represents hydrogen.
  • R 1 represents hydrogen, methyl or ethyl, preferably hydrogen.
  • the compound according to formulas I or Il is selected from the group consisting of: (R)-5-(4-chloro-phenyl)-1-(2,4-dichloiOphenyl)-4,5-dihydro-1 H-pyrazol-3- carboxylic acid,
  • Another aspect of the invention is a medicament comprising at least one combination of compounds according to the invention and optionally one or more pharmaceutically acceptable excipients.
  • the medicament is for the regulation of triglyceride levels in the blood plasma and for the prophylaxis and/or treatment of disorders of the central nervous system, especially stroke, of disorders of the cardiovascular system and of of food intake disorders, preferably bulimia, anorexia, cachexia, obesity, type Il diabetus mellitus (non-insuline dependent diabetes mellitus), preferably obesity and diabetis.
  • the medicament is for the prophylaxis and/or treatment of disorders of the central nervous system, disorders of the immune system, disorders of the cardiovascular system, disorders of the endocrinous system, disorders of the respiratory system, disorders of the gastrointestinal tract or reproductive disorders.
  • the medicament is for the modulation of cannabinoid-receptors, preferably cannabinoid 1 (CBi) receptors, for the prophylaxis and/or treatment of disorders of the central nervous system, disorders of the immune system, disorders of the cardiovascular system, disorders of the endocrinous system, disorders of the respiratory system, disorders of the gastrointestinal tract or reproductive disorders.
  • CBDi cannabinoid 1
  • the medicament is for the prophylaxis and/or treatment of food intake disorders, preferably bulimia, anorexia, cachexia, obesity, type Il diabetus mellitus (non-insuline dependent diabetes mellitus), preferably obesity.
  • food intake disorders preferably bulimia, anorexia, cachexia, obesity, type Il diabetus mellitus (non-insuline dependent diabetes mellitus), preferably obesity.
  • the medicament is for the prophylaxis and/or treatment of psychosis.
  • the medicament is for the prophylaxis and/or treatment of alcohol abuse and/or addiction, nicotine abuse and/or addiction, drug abuse and/or addiction and/or medicament abuse and/or addiction, preferably drug abuse and/or addiction and/or nicotine abuse and/or addiction.
  • the medicament is for the prophylaxis and/or treatment of one or more disorders selected from the group consisting of schizophrenia, anxiety, depression, epilepsy, neurodegenerative disorders, cerebellar disorders, spinocerebellar disorders, cognitive disorders, cranial trauma, panic attacks, peripheric neuropathy, glaucoma, migraine, Morbus Parkinson, Morbus Huntington, Morbus Alzheimer, Raynaud's disease, tremblement disorders, compulsive disorders, senile dementia, thymic disorders, tardive dyskinesia, bipolar disorders; bone disorders including osteoporosis or Paget's disease of bone; cancer, preferably for the prophylaxis and/or treatment of one or more types of cancer selected from the group consisting of brain cancer, bone cancer, lip cancer, mouth cancer, esophageal cancer, stomach cancer, liver cancer, bladder cancer, pancreas cancer, ovary cancer, cervical cancer, lung cancer, breast cancer, skin camcer, colon cancer, bowl cancer and prostate
  • Said medicaments may also comprise any combination of one or more of the substituted pyrazoline compounds of general formula I given above, stereoisomers thereof, corresponding N-oxides thereof, physiologically acceptable salts thereof or physiologically acceptable solvates thereof.
  • medicaments are suitable for the prophylaxis and/or treatment of alcohol abuse, drug abuse and/or medicament abuse, preferably drug abuse and the treatment of obesity.
  • Medicaments and/or drugs which are frequently the subject of misuse include opioids, barbiturates, cannabis, cocaine, amphetamines, phencyclidine, hallucinogens and benzodiazepines.
  • the medicament according to the present invention may be in any form suitable for the application to humans and/or animals, preferably humans including infants, children and adults and can be produced by standard procedures known to those skilled in the art.
  • the composition of the medicament may vary depending on the route of administration.
  • the medicament of the present invention may for example be administered parentally in combination with conventional injectable liquid carriers, such as water or suitable alcohols.
  • conventional pharmaceutical excipients for injection such as stabilizing agents, solubilizing agents, and buffers, may be included in such injectable compositions.
  • These medicaments may for example be injected intramuscularly, intraperitoneally, or intravenously.
  • Solid oral compositions (which are preferred as are liquid ones) may be prepared by conventional methods of blending, filling or tabletting. Repeated blending operations may be used to distribute the active agent throughout those compositions employing large quantities of fillers. Such operations are conventional in the art.
  • the tablets may for example be prepared by wet or dry granulation and optionally coated according to the methods well known in normal pharmaceutical practice., in particular with an enteric coating.
  • the mentioned formulations will be prepared using standard methods such as those described or referred to in the Spanish and US Pharmacopeias and similar reference texts.
  • Medicaments according to the present invention may also be formulated into orally administrable compositions containing one or more physiologically compatible carriers or excipients, in solid or liquid form. These compositions may contain conventional ingredients such as binding agents, fillers, lubricants, and acceptable wetting agents.
  • the compositions may take any convenient form, such as tablets, pellets, capsules, lozenges, aqueous or oily solutions, suspensions, emulsions, or dry powdered forms suitable for reconstitution with water or other suitable liquid medium before use, for immediate or retarded release.
  • liquid oral forms for administration may also contain certain additives such as sweeteners, flavoring, preservatives, and emulsifying agents.
  • Non-aqueous liquid compositions for oral administration may also be formulated, containing edible oils. Such liquid compositions may be conveniently encapsulated in e.g., gelatin capsules in a unit dosage amount.
  • compositions of the present invention may also be administered topically or via a suppository.
  • the daily dosage for humans and animals may vary depending on factors that have their basis in the respective species or other factors, such as age, sex, weight or degree of illness and so forth.
  • the daily dosage for humans may preferably be in the range fromi to 2000, preferably 1 to 1500, more preferably 1 to 1000 milligrams of active substance to be administered during one or several intakes per day.
  • Another preferred aspect of the invention is the use of at least one substituted pyrazoline compound of formula I or Il according to the invention or at least one combination of compounds according to the invention (and optionally one or more pharmaceutically acceptable excipients), for the preparation of a medicament for the regulation of triglyceride levels in the blood plasma and for the prophylaxis and/or treatment of disorders of the central nervous system, especially stroke, of disorders of the cardiovascular system and of food intake disorders, especially bulimia, anorexia, cachexia, obesity, type Il diabetus mellitus (non-insuline dependent diabetes mellitus), preferably obesity and diabetis.
  • Another preferred aspect of the invention is the use of at least one substituted pyrazoline compound of formaula I or Il according to the invention (and optionally one or more pharmaceutically acceptable excipients,) for the preparation of a medicament for the prophylaxis and/or treatment of disorders of the central nervous system, disorders of the immune system, disorders of the cardiovascular system, disorders of the endocrinous system, disorders of the respiratory system, disorders of the gastrointestinal tract or reproductive disorders.
  • Another preferred aspect of the invention is the use of at least one combination of compounds according to the invention (and optionally one or more pharmaceutically acceptable excipients,) for the preparation of a medicament for the modulation of cannabinoid-receptors, preferably cannabinoid 1 (CB-i) receptors, for the prophylaxis and/or treatment of disorders of the central nervous system, disorders of the immune system, disorders of the cardiovascular system, disorders of the endocrinous system, disorders of the respiratory system, disorders of the gastrointestinal tract or reproductive disorders.
  • CBD-i cannabinoid 1
  • Another preferred aspect of the invention is the use of at least one substituted pyrazoline compound of formula I or Il according to the invention or at least one combination of compounds according to the invention (and optionally one or more pharmaceutically acceptable excipients), for the preparation of a medicament for the prophylaxis and/or treatment of food intake disorders, preferably bulimia, anorexia, cachexia, obesity, type Il diabetus mellitus (non-insuline dependent diabetes mellitus), preferably obesity.
  • Another preferred aspect of the invention is the use of at least one substituted pyrazoline compound of formula I or Il according to the invention or at least one combination of compounds according to the invention (and optionally one or more pharmaceutically acceptable excipients), for the preparation of a medicament for the prophylaxis and/or treatment of psychosis.
  • Another preferred aspect of the invention is the use of at least one substituted pyrazoline compound of formula I or Il according to the invention or at least one combination of compounds according to the invention (and optionally one or more pharmaceutically acceptable excipients), for the preparation of a medicament for the prophylaxis and/or treatment of alcohol abuse and/or addiction, nicotine abuse and/or addiction, medicament abuse and/or addiction and/or drug abuse and/or addiction, preferably drug abuse and/or addiction or nicotine abuse and/or addiction.
  • Another preferred aspect of the invention is the use of at least one substituted pyrazoline compound of formula I or Il according to the invention or at least one combination of compounds according to the invention (and optionally one or more pharmaceutically acceptable excipients), for the preparation of a medicament for the prophylaxis and/or treatment of one or more disorders selected from the group consisting of schizophrenia, anxiety, depression, epilepsy, neurodegenerative disorders, cerebellar disorders, spinocerebellar disorders, cognitive disorders, cranial trauma, panic attacks, peripheric neuropathy, glaucoma, migraine, Morbus Parkinson, Morbus Huntington, Morbus Alzheimer, Raynaud's disease, tremblement disorders, compulsive disorders, senile dementia, thymic disorders, tardive dyskinesia, bipolar disorders; bone disorders including osteoporosis or Paget's disease of bone; cancer, preferably for the prophylaxis and/or treatment of one or more types of cancer selected from the group consisting of brain cancer, bone cancer, lip cancer, mouth cancer
  • Another preferred aspect of the invention is a method of regulating triglyceride levels in the blood plasma, a method for treating disorders of the central nervous system, especially stroke, disorders of the cardiovascular system or of food intake disorders, especially bulimia, anorexia, cachexia, obesity, type Il diabetus mellitus (non-insuline dependent diabetes mellitus), preferably obesity and diabetis, comprising administering to a subject, preferably a human, a therapeutically effective amount of one or more of the pyrazoline compounds or mixtures as described herein.
  • Another preferred aspect of the invention is a method of treating disorders of the central nervous system, disorders of the immune system, disorders of the cardiovascular system, disorders of the endocrinous system, disorders of the respiratory system, disorders of the gastrointestinal tract or reproductive disorders, comprising administering to a subject, preferably a human, a therapeutically effective amount of one or more of the pyrazoline compounds or mixtures as described herein.
  • Another preferred aspect of the invention is a method of treating psychosis, comprising administering to a subject, preferably a human, a therapeutically effective amount of one or more of the pyrazoline compounds or mixtures as described herein.
  • Another preferred aspect of the invention is a method for treating alcohol abuse and/or addiction, nicotine abuse and/or addiction, medicament abuse and/or addiction and/or drug abuse and/or addiction, preferably drug abuse and/or addiction or nicotine abuse and/or addiction, comprising administering to a subject, preferably a human, a therapeutically effective amount of one or more of the pyrazoline compounds or mixtures as described herein.
  • Another preferred aspect of the invention is a method of treating one or more disorders selected from the group consisting of schizophrenia, anxiety, depression, epilepsy, neurodegenerative disorders, cerebellar disorders, spinocerebellar disorders, cognitive disorders, cranial trauma, panic attacks, peripheric neuropathy, glaucoma, migraine, Morbus Parkinson, Morbus Huntington, Morbus Alzheimer, Raynaud's disease, tremblement disorders, compulsive disorders, senile dementia, thymic disorders, tardive dyskinesia, bipolar disorders; bone disorders including osteoporosis or Paget's disease of bone; cancer, preferably for the prophylaxis and/or treatment of one or more types of cancer selected from the group consisting of brain cancer, bone cancer, lip cancer, mouth cancer, esophageal cancer, stomach cancer, liver cancer, bladder cancer, pancreas cancer, ovary cancer, cervical cancer, lung cancer, breast cancer, skin camcer, colon cancer, bowl cancer and prostate cancer, more preferably for the prophylaxis and
  • Another preferred aspect of the invention is the use of at least one substituted pyrazoline compound of general formula I
  • R 1 represents hydrogen or a linear or branched, substituted or unsubstituted, saturated or unsaturated, Ci-4-alkyl group
  • R 10 and optionally R 11 for each substituent independently represent linear or branched Ci -6 alkyl
  • a medicament for the regulation of triglyceride levels in the blood plasma and for the prophylaxis and/or treatment of disorders of disorders of the central nervous system, especially stroke, of disorders of the cardiovascular system and of food intake disorders, especially bulimia, anorexia, cachexia, obesity, type Il diabetus mellitus (non-insuline dependent diabetes mellitus), preferably obesity and diabetis.
  • Another preferred aspect of the invention is the use of at least one substituted pyrazoline compound of general formula I
  • R 1 represents hydrogen or a linear or branched, substituted or unsubstituted, saturated or unsaturated, Ci-4-alkyl group,
  • a medicament for the regulation of triglyceride levels in the blood plasma and for the prophylaxis and/or treatment of disorders of disorders of the central nervous system, especially stroke, of disorders of the cardiovascular system and of food intake disorders, especially bulimia, anorexia, cachexia, obesity, type Il diabetus mellitus (non-insuline dependent diabetes mellitus), preferably obesity and diabetis.
  • neither of R 2 , R 3 or R 4 may represent SO 2 R 8 in para-position with R 8 being methyl.
  • Another preferred aspect of the invention is the use for the manufacture of a medicament of at least one substituted pyrazoline compound of formula I for which at least one of R 2 , R 3 or R 4 represents hydrogen, while at least one of R 2 , R 3 or R 4 is different from hydrogen for the manufacture of a medicamentfor the regulation of triglyceride levels in the blood plasma and for the prophylaxis and/or treatment of disorders of disorders of the central nervous system, especially stroke, of disorders of the cardiovascular system and of food intake disorders, especially bulimia, anorexia, cachexia, obesity, type Il diabetus mellitus (non-insuline dependent diabetes mellitus), preferably obesity and diabetis.
  • Another preferred aspect of the invention is the use of at least one substituted pyrazoline compound of formula I for which at least on of R 5 , R 6 or R 7 represents hydrogen, while at least one R 5 , R 6 or R 7 is different from hydrogen for the manufacture of a medicamentfor the regulation of triglyceride levels in the blood plasma and for the prophylaxis and/or treatment of disorders of disorders of the central nervous system, especially stroke, of disorders of the cardiovascular system and of food intake disorders, especially bulimia, anorexia, cachexia, obesity, type Il diabetus mellitus (non-insuline dependent diabetes mellitus), preferably obesity and diabetis.
  • Another preferred aspect of the invention is the use of at least one substituted pyrazoline compound of formula I for which R 2 , R 3 and R 4 independently of each other represent hydrogen, a linear or branched d- ⁇ -alkyl group, a halogen atom, or CF 3 , preferably R 2 , R 3 and R 4 independently of each other represent hydrogen, methyl, ethyl, F, Cl, Br and CF 3 for the manufacture of a medicamentfor the regulation of triglyceride levels in the blood plasma and for the prophylaxis and/or treatment of disorders of disorders of the central nervous system, especially stroke, of disorders of the cardiovascular system and of food intake disorders, especially bulimia, anorexia, cachexia, obesity, type Il diabetus mellitus (non-insuline dependent diabetes mellitus), preferably obesity and diabetis.
  • Another preferred aspect of the invention is the use of at least one substituted pyrazoline compound of formula I for which R 5 , R 6 and R 7 independently of each other represent hydrogen, a linear or branched Ci- ⁇ -alkyl group, a halogen atom, or CF 3 , preferably R 5 , R 6 and R 7 independently of each other represent hydrogen, methyl, ethyl, F, Cl, Br and CF 3 for the manufacture of a medicamentfor the regulation of triglyceride levels in the blood plasma and for the prophylaxis and/or treatment of disorders of disorders of the central nervous system, especially stroke, of disorders of the cardiovascular system and of food intake disorders, especially bulimia, anorexia, cachexia, obesity, type Il diabetus mellitus (non-insuline dependent diabetes mellitus), preferably obesity and diabetis.
  • R 5 , R 6 and R 7 independently of each other represent hydrogen, a linear or branched Ci- ⁇ -alkyl group, a halogen atom, or
  • Another preferred aspect of the invention is the use of at least one substituted pyrazoline compound of formula I for which R 2 represents a chlorine atom in the 4- position of the phenyl ring, while R 3 and R 4 represent hydrogen for the manufacture of a medicamentfor the regulation of triglyceride levels in the blood plasma and for the prophylaxis and/or treatment of disorders of disorders of the central nervous system, especially stroke, of disorders of the cardiovascular system and of food intake disorders, especially bulimia, anorexia, cachexia, obesity, type Il diabetus mellitus (non-insuline dependent diabetes mellitus), preferably obesity and diabetis.
  • Another preferred aspect of the invention is the use of at least one substituted pyrazoline compound of formula I for which R 5 and R 6 each represent a chlorine atoms in the 2- and 4-position of the phenyl ring, while R 7 represents hydrogen for the manufacture of a medicamentfor the regulation of triglyceride levels in the blood plasma and for the prophylaxis and/or treatment of disorders of disorders of the central nervous system, especially stroke, of disorders of the cardiovascular system and of food intake disorders, especially bulimia, anorexia, cachexia, obesity, type Il diabetus mellitus (non-insuline dependent diabetes mellitus), preferably obesity and diabetis.
  • Another preferred aspect of the invention is the use of at least one substituted pyrazoline compound of formula I for which R 1 represents hydrogen, methyl or ethyl, preferably hydrogen for the manufacture of a medicamentfor the regulation of triglyceride levels in the blood plasma and for the prophylaxis and/or treatment of disorders of disorders of the central nervous system, especially stroke, of disorders of the cardiovascular system and of food intake disorders, especially bulimia, anorexia, cachexia, obesity, type Il diabetus mellitus (non-insuline dependent diabetes mellitus), preferably obesity and diabetis.
  • Another preferred aspect of the invention is the use of at least one substituted pyrazoline compound of formula wherein the compound of general formula (I) is represented by a compound of general formula (II)
  • R 1 represents hydrogen or a linear or branched, substituted or unsubstituted, saturated or unsaturated, Ci-4-alkyl group,
  • R 12 , R 13 , R 14 or R 15 independently of each other represent a linear or branched d-e-alkyl group, a linear or branched Ci-e-alkoxy group, a halogen atom, CH 2 F, CHF 2 , CF 3 , CN, OH, NO 2 , SH 1 NH 2 , hydrogen, methyl, ethyl, F, Cl, Br and CF 3 ,
  • a medicament for the manufacture of a medicamentfor the regulation of triglyceride levels in the blood plasma and for the prophylaxis and/or treatment of disorders of disorders of the central nervous system, especially stroke, of disorders of the cardiovascular system and of food intake disorders, especially bulimia, anorexia, cachexia, obesity, type Il diabetus mellitus (non-insuline dependent diabetes mellitus), preferably obesity and diabetis.
  • Another embodiment of the invention is the use of at least one substituted pyrazoline compound of formula Il for which R 12 and R 13 independently of each other represent hydrogen, a linear or branched Ci- 6 -alkyl group, a halogen atom, or CF 3 , preferably R 12 and R 13 independently of each other represent hydrogen, methyl, ethyl, F, Cl, Br and CF 3 for the manufacture of a medicamentfor the regulation of triglyceride levels in the blood plasma and for the prophylaxis and/or treatment of disorders of disorders of the central nervous system, especially stroke, of disorders of the cardiovascular system and of food intake disorders, especially bulimia, anorexia, cachexia, obesity, type Il diabetus mellitus (non-insuline dependent diabetes mellitus), preferably obesity and diabetis.
  • Another embodiment of the invention is the use of at least one substituted pyrazoline compound of formula Il for which R 14 , and R 15 independently of each other represent hydrogen, a linear or branched Ci-6-alkyl group, a halogen atom, or CF 3 , preferably R 14 and R 15 independently of each other represent hydrogen, methyl, ethyl, F, Cl, Br and CF3for the manufacture of a medicamentfor the regulation of triglyceride levels in the blood plasma and for the prophylaxis and/or treatment of disorders of disorders of the central nervous system, especially stroke, of disorders of the cardiovascular system and of food intake disorders, especially bulimia, anorexia, cachexia, obesity, type Il diabetus mellitus (non-insuline dependent diabetes mellitus), preferably obesity and diabetis.
  • Another embodiment of the invention is the use of at least one substituted pyrazoline compound of formula Il for which R 13 represents Cl and R 12 represents hydrogen for the manufacture of a medicamentfor the regulation of triglyceride levels in the blood plasma and for the prophylaxis and/or treatment of disorders of disorders of the central nervous system, especially stroke, of disorders of the cardiovascular system and of food intake disorders, especially bulimia, anorexia, cachexia, obesity, type Il diabetus mellitus (non-insuline dependent diabetes mellitus), preferably obesity and diabetis.
  • Another preferred embodiment of the invention is the use of at least one substituted pyrazoline compound of formula Il for which R 14 and R 15 each represent Cl for the manufacture of a medicamentfor the regulation of triglyceride levels in the blood plasma and for the prophylaxis and/or treatment of disorders of disorders of the central nervous system, especially stroke, of disorders of the cardiovascular system and of food intake disorders, especially bulimia, anorexia, cachexia, obesity, type Il diabetus mellitus (non-insuline dependent diabetes mellitus), preferably obesity and diabetis.
  • Another preferred embodiment of the invention is the use of at least one substituted pyrazoline compound of formula Il for which R 1 represents hydrogen, methyl or ethyl, preferably hydrogen for the manufacture of a medicamentfor the regulation of triglyceride levels in the blood plasma and for the prophylaxis and/or treatment of disorders of disorders of the central nervous system, especially stroke, of disorders of the cardiovascular system and of food intake disorders, especially bulimia, anorexia, cachexia, obesity, type Il diabetus mellitus (non-insuline dependent diabetes mellitus), preferably obesity and diabetis.
  • Another embodiment of the invention is the use of at least one substituted pyrazoline compound of formula I or Il for which the compound according to formulas I or Il is selected from the group consisting of:
  • a medicament for the manufacture of a medicamentfor the regulation of triglyceride levels in the blood plasma and for the prophylaxis and/or treatment of disorders of disorders of the central nervous system, especially stroke, of disorders of the cardiovascular system and of food intake disorders, especially bulimia, anorexia, cachexia, obesity, type Il diabetus mellitus (non-insuline dependent diabetes mellitus), preferably obesity and diabetis.
  • pyrazoline compounds as defined herein and optionally one or more pharmaceutically acceptable excipients, for the preparation of a medicament for the treatment of metabolic syndrome.
  • the metabolic syndrome is characterized by an interaction of several physiological parameters such as triglycerides, lipids, blood pressure, glucose levels and insuline levels.
  • Another aspect of the invention is the use of one or more pyrazoline compounds as defined herein for the manufacture of a medicament for improvent of cardiovascular and/or metabolic risk factors, such as one or more of the following factors:
  • Elevated triglycerides whereby elevated levels of triglycerides are preferably understood as being > 150 mg/dl,
  • Low HDL cholesterol whereby low levels of HDL cholesterol are preferably understood as being ⁇ 40 mg/dl in men and ⁇ 50 mg/dl in women,
  • Hypertension whereby hypertension is preferably understood as being > 130/85 mmHg,
  • Impaired fasting glucose whereby impaired fasting glucose levels are preferably understood as being > 110 mg/dl,
  • Another aspect of the invention is the use of one or more pyrazoline compounds as defined herein for the manufacture of a medicament for the treatment of the weight independent aspects of metabolic syndrome.
  • Another aspect of the invention is a method for improving cardiovascular and/or metabolic risk factors, such as one or more of the following factors:
  • Elevated triglycerides whereby elevated levels of triglycerides are preferably understood as being > 150 mg/dl,
  • Low HDL cholesterol whereby low levels of HDL cholesterol are preferably understood as being ⁇ 40 mg/dl in men and ⁇ 50 mg/dl in women,
  • Hypertension whereby hypertension is preferably understood as being > 130/85 mmHg,
  • Impaired fasting glucose whereby impaired fasting glucose levels are preferably understood as being > 110 mg/dl,
  • a subject preferably a human.
  • Another aspect of the invention is a method for treating of the weight independent aspects of metabolic syndrome.
  • Example 0 represent a compound according to formula I or II.
  • step a) 4-(4-chlorophenyl)-2-oxo-3-butenoic acid obtained according to step a) (12.6 g, 60 mmoles), 2,4-dichlorophenylhydrazine hydrochloride (12.8 g, 60 mmoles) and glacial acetic acid (200 ml_) were mixed under a nitrogen atmosphere and heated to reflux for 4 hours, cooled down to room temperature (approximately 25 0 C) and given into ice-water, whereby a sticky mass was obtained, which was extracted with methylene chloride. The combined methylene chloride fractions were washed with water, dried with sodium sulfate, filtered and evaporated to dryness to give a pale yellow solid (12.7 g, 57% of theoretical yield).
  • Acid represents racemic 5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4,5-dihydro- pyrazole-3-carboxylic acid
  • R-Acid represents the respective derivative of (R)-5-(4-chlorophenyl)-1-(2 ) 4- dichlorophenyl)-4,5-dihydro-pyrazole-3-carboxylic acid
  • S-Acid represents the respective derivative of (S)-5-(4-chlorophenyl)-1-(2,4- dichlorophenyl)-4,5-dihydro-pyrazole-3-carboxylic acid
  • Process A A solution of the chiral base was added on top of a solution of the racemic acid at room temperature.
  • Process C A solution of the racemic acid was added on top of a solution of the chiral base. The mixture was heated to reflux and solvent was added until dissolution was complete. The solution was left to crystallisation at r.t.
  • Process D The chiral base was directly added on top of a solution of the racemic acid at room temperature.
  • Process E The chiral base was directly added on top of a solution of the racemic acid at reflux temperature.
  • Process F The solution of the salt was evaporated to dryness. The residue was dissolved in a minimum amount of the solvent under reflux heating. The solution was left to crystallisation at r.t.
  • the purity of the isolated salt was comparable to the one of the salt obtained directly from the resolution of the racemate. Consequently, the same purification process as described above could be applied.
  • the ratio of the enantiomers as determined by capilar electrophoresis was: 99 % of (S)-5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4,5-dihydro-pyrazole-3-carboxylic acid Brucine
  • the chirality of the enantiomer that crystallized with Brucine (ee 98 %) was determined via x-ray crystallography and corresponds to the S-enantiomer. Accordingly, the other enantiomer that crystallized with (+)-cinchonine is the corresponding R-enantiomer.
  • the purity of the isolated salt was comparable to the one of the salt obtained directly from the resolution of the racemate. Consequently, the same purification process as described above could be applied.
  • the Examples 1 to 6 represent compounds according to formula X.
  • N-aminopiperidine (0.6 ml_, 5.6 mmoles) and triethylamine (4 mL) were dissolved in methylene chloride (25 ml_).
  • methylene chloride 25 ml_.
  • the resulting mixture was ice- cooled down to 0 0 C and a solution of 5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4,5- dihydro-pyrazole-3-carboxylic acid chloride obtained in step (a) in methylene chloride (15 mL) was added dropwise.
  • the resulting reaction mixture was stirred at room temperature (approximately 25 0 C) overnight.
  • This compound was obtained in form of an oil.
  • the compound according to example 0 is an inhibitor of high blood levels of triglicerides. This effect is probed in obese mice fed with high fat diet. In the following paragraphs the method of this study is described.
  • mice B6 Lep ob/ob obtained from Charles River (France). Mice are divided in 3 groups: I (control), Il (vehicle), III (example 0).
  • the animals of the group I receive the standard diet (D-12450B, Research Diets, NJ, USA).
  • the animals of the groups Il and III are fed with a High Fat Diet (D-12492, Research Diets, NJ, USA), in both cases for 7 weeks (References 1 and 2).
  • mice receive the vehicle (10 ml/kg/day, po, of the aqueous solution of acacia gum, 5% WA/).
  • Group I does not receive any treatment.
  • the three groups of mice have the same diet than in the previous period.
  • the blood levels of triglicerides of the animals are determined.
  • mice receiving a high fat diet are - after a feeding period of 6 days - either treated p.o. with vehicle (0,5 % HPMC) or with the compound according to example 0 (30 mg/kg/day p.o.).
  • TG levels in blood are determined on day 28 after beginning of the treatment. 77

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La présente invention concerne des composés de pyrazoline substitués, leurs méthodes de préparation et des médicaments contenant ces composés. Elle concerne également l'utilisation des composés pour la préparation d'un médicament destiné au traitement d'êtres humains et d'animaux.
PCT/EP2006/006976 2005-07-15 2006-07-15 Composes de pyrazoline substitues, leur preparation et leur utilisation comme medicaments WO2007009702A2 (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP05384022A EP1743889A1 (fr) 2005-07-15 2005-07-15 Composés de pyrazolines substituées ayant une stereochimie predeterminèe pour réduire des triglycerides dans le sang
EP05384022.9 2005-07-15
US70543605P 2005-08-05 2005-08-05
US60/705,436 2005-08-05

Publications (2)

Publication Number Publication Date
WO2007009702A2 true WO2007009702A2 (fr) 2007-01-25
WO2007009702A3 WO2007009702A3 (fr) 2007-04-05

Family

ID=36950414

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2006/006976 WO2007009702A2 (fr) 2005-07-15 2006-07-15 Composes de pyrazoline substitues, leur preparation et leur utilisation comme medicaments

Country Status (2)

Country Link
ES (1) ES2336883B1 (fr)
WO (1) WO2007009702A2 (fr)

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1209326A (en) * 1966-09-27 1970-10-21 Carter Wallace The preparation of 3-methyl-5-pyrazole carboxylic acid amides
WO1988005046A2 (fr) * 1987-01-05 1988-07-14 E.I. Du Pont De Nemours And Company Pyrazolines insecticides
WO2002080909A1 (fr) * 2001-04-06 2002-10-17 Laboratorios Del Dr. Esteve, S.A. Utilisation de derives de pyrazolines dans l'elaboration d'un medicament pour la prevention et/ou le traitement de maladies proliferatives cellulaires
WO2005077909A1 (fr) * 2004-02-17 2005-08-25 Laboratorios Dr. Esteve S.A. Composes de pyrazoline substitues permettant de reduire le taux de triglycerides dans le sang

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2137138B1 (es) * 1998-05-29 2000-09-16 Esteve Labor Dr Derivados de pirazolinas, su preparacion y su aplicacion como medicamentos.
US20040122033A1 (en) * 2002-12-10 2004-06-24 Nargund Ravi P. Combination therapy for the treatment of obesity
ES2326725B1 (es) * 2005-07-15 2010-05-11 Laboratorios Del Dr. Esteve, S.A. Uso de compuestos de pirazolina sustituidos para el tratamiento de trastornos alimentarios, que incluyen la obesidad o el sindrome metabolico en pacientes con diabetes desarrollada.

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1209326A (en) * 1966-09-27 1970-10-21 Carter Wallace The preparation of 3-methyl-5-pyrazole carboxylic acid amides
WO1988005046A2 (fr) * 1987-01-05 1988-07-14 E.I. Du Pont De Nemours And Company Pyrazolines insecticides
WO2002080909A1 (fr) * 2001-04-06 2002-10-17 Laboratorios Del Dr. Esteve, S.A. Utilisation de derives de pyrazolines dans l'elaboration d'un medicament pour la prevention et/ou le traitement de maladies proliferatives cellulaires
WO2005077909A1 (fr) * 2004-02-17 2005-08-25 Laboratorios Dr. Esteve S.A. Composes de pyrazoline substitues permettant de reduire le taux de triglycerides dans le sang

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
ADAMS J ET AL: "Recent advances in the cannabinoids" EXPERT OPINION ON THERAPEUTIC PATENTS, ASHLEY PUBLICATIONS, GB, vol. 12, no. 10, 2002, pages 1475-1489, XP002353808 ISSN: 1354-3776 *
MESCHLER J P ET AL: "Inverse agonist properties of N-(piperidin-1-yl)-5-(4-chlorophenyl)- 1-(2, dichlorophenyl)-4-methyl-1H-pyrazole-3- carboxamide HCl (SR141716A) and 1-(2-chlorophenyl)-4-cyano-5-(4-methoxyphe nyl)-1H-pyr azole-3-carboxylic acid phenylamide (CP-272871) for the CB1 cannabinoid receptor" BIOCHEMICAL PHARMACOLOGY, PERGAMON, OXFORD, GB, vol. 60, 2000, pages 1315-1323, XP002262541 ISSN: 0006-2952 *

Also Published As

Publication number Publication date
ES2336883A1 (es) 2010-04-16
WO2007009702A3 (fr) 2007-04-05
ES2336883B1 (es) 2011-03-22

Similar Documents

Publication Publication Date Title
EP1718619A1 (fr) Composes de pyrazolines substituees pour reduire des triglycerides dans le sang
US7994200B2 (en) Cycloalkane-substituted pyrazoline derivatives, their preparation and use as medicaments
EP1757587A1 (fr) Composés de pyrazoline substituée, leur préparation et leur usage comme médicaments
EP1849775A1 (fr) Composés de pyrazoline substituées par les cycloalkanes, leur préparation et leur utilisation comme médicaments.
EP1743892A1 (fr) Composés pyrazoline substitués, leur préparation et utilisation comme médicaments
WO2007009706A2 (fr) Composes de pyrazoline substitues, leur preparation et utilisation comme medicaments
EP1637522A1 (fr) Composés de pyrazolines substituées pour réduire des triglycerides dans le sang
US7998996B2 (en) Substituted pyrazoline compounds for reducing triglycerides in blood
WO2007009702A2 (fr) Composes de pyrazoline substitues, leur preparation et leur utilisation comme medicaments
EP1746090A1 (fr) Composés de pyrazolines substituées ayant une stereochimie predeterminèe pour réduire des triglycerides dans le sang
WO2007009704A2 (fr) Utilisation de composes de pyrazoline substitues pour le traitement de troubles lies aux aliments, notamment l'obesite ou le syndrome metabolique chez des malades souffrant du diabete
EP1743889A1 (fr) Composés de pyrazolines substituées ayant une stereochimie predeterminèe pour réduire des triglycerides dans le sang
ES2337005B1 (es) Compuestos de pirazolina azepan o azocansustituidos, su preparacion ysu uso como medicamentos.
EP1749526A1 (fr) Utilisation des derivés de la pyrazoline pour le traitement des troubles alimentaires, comme l'obesité ou le syndrome métabolique chez les patients diabetiques
ES2325569B1 (es) Compuestos de pirazolina cicloalcanosustituidos, su preparacion y su uso como medicamentos.
EP1743638A1 (fr) Formulations pharmaceutiques des derivés de la pyrazoline
ES2327204B1 (es) Compuestos de pirazolina octahidropentalensustituidos, su preparacion y su uso como medicamentos.
WO2007009707A2 (fr) Utilisation de composes a base de pyrazoline substitues pour le traitement de maladies liees a la coagulation
EP1749527A1 (fr) Utilisation des derivés du pyrazole pour le traitement du syndrome métabolique
ES2327379B1 (es) Compuestos de pirazolina indolinsustituidos, su preparacion y su uso como medicamentos.
MXPA06009335A (en) Substituted pyrazoline compounds for reducing triglycerides in blood
WO2007009699A2 (fr) Utilisation de composes pyrazoliniques substitues et de leurs derives contre des affections associees au systeme des cannabinoides
WO2007009700A2 (fr) Utilisation de composes pyrazoliniques substitues pour le traitement de parametres des lipides du syndrome metabolique
EP1849783A1 (fr) Composés de pyrazoline substituées par les octahydrocyclopentalenes, leur préparation et leur utilisation comme médicaments.
EP1849784A1 (fr) Dérivés de la pyrazoline Indoline-substituée, leur préparation and utilisation comme médicaments

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application
ENP Entry into the national phase

Ref document number: 200850012

Country of ref document: ES

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

WWW Wipo information: withdrawn in national office

Country of ref document: DE

122 Ep: pct application non-entry in european phase

Ref document number: 06762618

Country of ref document: EP

Kind code of ref document: A2

WWP Wipo information: published in national office

Ref document number: 200850012

Country of ref document: ES

Kind code of ref document: A

点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载